文献速递淋巴瘤

肿瘤体积与体能状态模型预测弥漫性大B细胞淋巴瘤治疗前结局

A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma.
PubMed 文献 · Blood Adv · 2022-01-01

该研究在REMARC试验301例老年患者中建立总代谢肿瘤体积>220 cm3且体能状态≥2的预后模型,并在PETAL、GOYA两项临床试验及真实世界共2174例患者中验证。模型将患者分为低、中、高危三组,多数系列中可显著区分结局,且优于国际预后指数。

要点

  • 总代谢肿瘤体积>220 cm3且ECOG体能状态≥2的组合可在治疗前识别侵袭性大B细胞淋巴瘤高危患者。
  • 该模型在PETAL、GOYA及真实世界系列中均能显著区分低、中、高危三组结局。
  • 该组合模型在多数系列中预测无进展生存和总生存的C指数优于国际预后指数。

核心结论

  • 总代谢肿瘤体积>220 cm3与ECOG体能状态≥2的组合是一种简单的临床模型,可在治疗前识别侵袭性大B细胞淋巴瘤的风险分层。

研究设计与样本

  • 预后模型建立基于REMARC试验(#NCT01122472)的301例老年患者,验证基于PETAL试验510例、GOYA试验1315例及欧洲和美国真实世界诊所349例,共2174例各年龄段患者。

主要发现

  • 低危(无危险因素)、中危(1个危险因素)、高危(2个危险因素)三组在多数系列中显著区分结局。
  • 在PETAL、GOYA和真实世界系列中,2个危险因素患者的结局差于无危险因素患者。
  • 中危患者结局也显著差于无危险因素患者。
  • 总代谢肿瘤体积/东部肿瘤协作组体能状态组合在多数系列中预测无进展生存和总生存的C指数优于国际预后指数。

关键数值与推荐

  • 总代谢肿瘤体积>220 cm3由氟-18氟代脱氧葡萄糖正电子发射断层扫描联合计算机断层扫描测定。
  • 体能状态评分采用东部肿瘤协作组体能状态≥2。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Aggressive large B-cell lymphoma (LBCL) has variable outcomes. Current prognostic tools use factors for risk stratification that inadequately identify patients at high risk of refractory disease or relapse before initial treatment. A model associating 2 risk factors, total metabolic tumor volume (TMTV) >220 cm3 (determined by fluorine-18 fluorodeoxyglucose positron emission tomography coupled with computed tomography) and performance status (PS) ≥2, identified as prognostic in 301 older patients in the REMARC trial (#NCT01122472), was validated in 2174 patients of all ages treated in 2 clinical trials, PETAL (Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas; N = 510) and GOYA (N = 1315), and in real-world clinics (N = 349) across Europe and the United States. Three risk categories, low (no factors), intermediate (1 risk factor), and high (2 risk factors), significantly discriminated outcome in most of the series. Patients with 2 risk factors had worse outcomes than patients with no risk factors in the PETAL, GOYA, and real-world series. Patients with intermediate risk also had significantly worse outcomes than patients with no risk factors. The TMTV/Eastern Cooperative Oncology Group-PS combination outperformed the International Prognostic Index with a positive C-index for progression-free survival and overall survival in most series. The combination of high TMTV > 220 cm3 and ECOG-PS ≥ 2 is a simple clinical model to identify aggressive LBCL risk categories before treatment. This combination addresses the unmet need to better predict before treatment initiation for aggressive LBCL the patients likely to benefit the most or not at all from therapy.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Thieblemont C, Chartier L, Dührsen U, et al. A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma. Blood Adv. 2022. PMID: 36044385. doi:10.1182/bloodadvances.2021006923

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。